Stephane ROCHE, PhD, HDR

CEO & CTO

Researcher, Stéphane ROCHE holds a PhD in Biological and Medical Engineering and is a former University Hospital Assistant of the Grenoble Hospitals. Stéphane ROCHE also holds a Habilitation to Supervise Research. He has worked in the hospitals of Grenoble, Montpellier and Marseille. He has an important background in medical genetics, medical biochemistry and innovative therapies (ORCID, HAL).

Haemochromatosis

QSMetric Potential Indications -Haemochromatosis

QSMetric Potential Indications – Haemochromatosis Discover a potential indication of QSMetric™…

QSMetric Potential Indications – Neurodegeneration with brain iron accumulation

QSMetric Potential Indications – Neurodegeneration with brain iron accumulation

QSMetric Potential Indications – Neurodegeneration with brain iron accumulation Discover a pot…

QSMetric Potential Indications – Huntington disease

QSMetric Potential Indications – Huntington disease

QSMetric Potential Indications – Huntington disease Discover a potential indication of QSMetri…

QSMetric Potential Indications – Traumatic brain injury

QSMetric Potential Indications – Traumatic brain injury

QSMetric Potential Indications – Traumatic brain injury Discover a potential indication of QSM…

QSMetric Potential Indications – Multiple sclerosis

QSMetric Potential Indications – Multiple sclerosis

QSMetric Potential Indications – Multiple sclerosis Discover a potential indication of QSMetri…

QSMetric Potential Indications – Vascular dementia

QSMetric Potential Indications – Vascular dementia

QSMetric Potential Indications – Vascular dementia Discover a potential indication of QSMetric…

QSMetric Potential Indications – Parkinson disease

QSMetric Potential Indications – Parkinson disease

QSMetric Potential Indications – Parkinson disease Discover a potential indication of QSMetric…

QSMetric Potential Indications – Alzheimer’s and related diseases

QSMetric Potential Indications – Alzheimer’s and related diseases

QSMetric Potential Indications – Alzheimer’s and related diseases Discover a potential i…

QSMetric Potential Indications – [Context]  Iron, iron accumulation and ferroptosis

QSMetric Potential Indications – [Context] Iron, iron accumulation and ferroptosis

QSMetric Potential Indications [Context] Iron, iron accumulation and ferroptosis Dr ROCHE Stéphane B…

Stephane Roche becomes CEO of Ventio

Stephane Roche becomes CEO of Ventio

Stephane Roche becomes CEO of Ventio Technical Director for the past 2 years, Dr Stephane Roche took…

SFRMBM 2023

SFRMBM 2023

Miguel Guevara1, Davy Cam4, Jacques Badagbon4, Stéphane Roche4, Michel Bottlaender3, Yann Cointepas1…

QMRLucca 2022

QMRLucca 2022

QSM4SENIOR: Quantitative susceptibility mapping in the aging of the healthy brain. Miguel Guevara1,2…

APP Ab38 Ab40 in FTD

APP Ab38 Ab40 in FTD

Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia Gabelle, Audr…

sAPP & Abeta in CSF

sAPP & Abeta in CSF

Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40 and 42 in…

Preanalytical guidelines

Preanalytical guidelines

Preanalytical guidelines for clinical proteomics investigation of biological fluids S Lehmann, S. Ro…

Biomarkers in CSF

Biomarkers in CSF

Les marqueurs biologiques protéiques du liquide céphalorachidien : caractéristiques et implications …

Autoantibody in CSF

Autoantibody in CSF

Auto-antibody profiling on high-density protein microarrays for biomarker discovery in the cerebrosp…

Clinical proteomics in CSF

Clinical proteomics in CSF

Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers Stéphane Roc…